The PE Ratio as of December 2024 (TTM) for BioAtla, Inc. (BCAB) is -0.37

According to BioAtla, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.37. This represents a change of -73.72% compared to the average of -1.41 of the last 4 quarters.

BioAtla, Inc. (BCAB) Historical PE Ratio (quarterly & annually)

How has BCAB PE Ratio performed in the past?

The mean historical PE Ratio of BioAtla, Inc. over the last ten years is -16.37. The current -0.37 PE Ratio has changed 126.02% with respect to the historical average. Over the past ten years (40 quarters), BCAB's PE Ratio was at its highest in in the September 2023 quarter at -0.61. The PE Ratio was at its lowest in in the December 2019 quarter at -123.01.

BioAtla, Inc. (BCAB) PE Ratio by Quarter and Year

Discovering the peaks and valleys of BioAtla, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BioAtla, Inc. (BCAB) Average PE Ratio

How has BCAB PE Ratio performed in the past?

The current PE Ratio of BioAtla, Inc. (BCAB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

BioAtla, Inc. (BCAB) PE Ratio vs. Peers

How is BCAB’s PE Ratio compared to its peers?

BioAtla, Inc.’s PE Ratio is greater than PMV Pharmaceuticals, Inc. (-1.47), greater than C4 Therapeutics, Inc. (-2.55), greater than Nautilus Biotechnology, Inc. (-3.09), greater than Century Therapeutics, Inc. (-0.67), greater than Passage Bio, Inc. (-0.58), greater than Ikena Oncology, Inc. (-1.24), greater than Olema Pharmaceuticals, Inc. (-2.95), greater than Aerovate Therapeutics, Inc. (-0.89), greater than Adagene Inc. (-2.67), greater than Acrivon Therapeutics, Inc. Common Stock (-3.08), greater than Rezolute, Inc. (-4.44), greater than AN2 Therapeutics, Inc. (-0.67), greater than Gracell Biotechnologies Inc. (-29.26), greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than Monte Rosa Therapeutics, Inc. (-4.84), greater than Design Therapeutics, Inc. (-7.53), greater than Erasca, Inc. (-4.56), greater than Foghorn Therapeutics Inc. (-3.45), greater than Shattuck Labs, Inc. (-0.76), greater than Kymera Therapeutics, Inc. (-18.55), greater than Nurix Therapeutics, Inc. (-8.05),

Build a custom stock screener for BioAtla, Inc. (BCAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioAtla, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioAtla, Inc. (BCAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioAtla, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.